[conference news] project decision making and pharmaceutical investment based on big data analysis and 2018 pharmaceutical intelligence data national tour · Shanghai Station

Project decision making and pharmaceutical investment based on big data analysis and 2018 pharmaceutical intelligence data national tour · Shanghai station time: April 10, 2018 (Tuesday 14:00-17:00) location: in the middle of January in Shanghai, the nationwide tour of pharmaceutical intelligence data began It has experienced three stops: Beijing, Guang'an and Guangzhou, and has been welcomed and praised by people in the pharmaceutical industry In April, we will continue to move forward This stop has come to the eastern part of our motherland - Charming Shanghai Let's have a look at it first and learn about the content and information of this tour 1、 Keynote speaker of Shanghai station Li Tianquan, senior engineer, co-founder of yaozhi.com, executive vice president of Chongqing Kangzhou pharmaceutical Big Data Application Research Institute and President of Yaozhi elite club Li Tianquan has been engaged in the research and development of the pharmaceutical industry for a long time He has undertaken a number of national and provincial research and development projects, obtained 5 national invention patents, served as the director of new drug research and development for many years, and successfully developed dozens of new products In recent years, Li Tianquan has been absorbed in the construction and utilization of medical database, and jointly established a professional China's leading medical big data service platform, yaozhi.com, which specializes in the retrieval and utilization of medical information He is good at interpreting industrial policies and medical hot information through the mining of professional data, in-depth analysis of the development status and trend of the pharmaceutical industry, and helping to make investment decisions The main content of the new trend of China's pharmaceutical research and development after the new policy of Medicine: since the clinical trial verification in July 2015, CFDA has intensively introduced many new policies, such as the reform of registration and classification of chemical drugs Since the implementation of the new policy, how does the business community respond, what profound changes have taken place in the direction of research and development, and what enterprises and policies need to be concerned about? This report will provide you with in-depth interpretation through detailed data Outline: 1 Relationship between policy change and R & D project selection; 2 Investment and R & D trend analysis after the new policy of medicine; 3 Application trend of chemical drug R & D after the registration and classification reform; 4 Latest policy interpretation (China's accession to ICH, etc., injection consistency evaluation); 5 Academic director and senior lecturer of Huang Wenfeng Institute of pharmaceutical intelligence, a hot investment spot worthy of attention [introduction] He graduated from Huazhong University of science and technology in 2008 and joined in yaozhi.com in 2018 He used to work in Shanghai pharmaceutical, Chongqing Laimei, Wanquan pharmaceutical holding and other well-known domestic listed enterprises During this period, he served as the director of the synthesis department and the project manager Familiar with pharmaceutical laws and regulations, pharmaceutical information retrieval and utilization, patent analysis, route development and design, process optimization, quality research and control, medium test certificate and production implementation, registration document preparation So far, 18 pilot projects, 10 pilot projects and 10 production projects have been completed under guidance, of which 6 API products have been put on the market (including sterile API) A total of 17 Chinese invention patents (11 for the first inventor and 4 for the second inventor) have been applied for So far, 6 patents have been authorized Title: application of pharmaceutical intelligence data in project decision-making and pharmaceutical investment Pharmaceutical intelligence data is a leading pharmaceutical database in China In 2017, a number of new databases and more functions have been added This training will take you to have an in-depth understanding of the retrieval function and analysis function of pharmaceutical intelligence database, and show you the application of pharmaceutical intelligence data in the field of project decision-making and pharmaceutical investment Outline: 1 Pharmaceutical intelligence data comprehensive retrieval system (enterprise analysis, R & D pattern, listed product pattern analysis, patent analysis) 2 Sales database (listed enterprise sales database, drug winning information, hospital sales data (under construction), medical insurance catalog) 3 How pharmaceutical intelligence data help project decision-making and pharmaceutical investment 2 Agenda of Shanghai station meeting 13:00-13:40 sign in 13: 40-14:00 opening speech 14:00-15:00 "drug R & D and trend under the new policy of medicine" (Li Tianquan) 15:00-15:20 tea break, interactive communication link 15:20-16:20 "Application of pharmaceutical intelligence data in project decision-making and pharmaceutical investment" (Huang Wenfeng) 16:30-17:00 interactive communication link 17:00 meeting conclusion III venue address of Shanghai Station Venue: 20 / F, China Insurance Building, No.166, Lujiazui East Road, Pudong New Area, Shanghai (Southwest Securities Co., Ltd.) 4 Application method 1 Nie Hongxing, database consultant of Chongqing Kangzhou big data Co., Ltd (Yaozhi network), Tel.: 17302301767 wechat: niehongxing 1224 2 In addition, you can directly click "national tour · Shanghai station" to apply Note: Chongqing Kangzhou big data Co., Ltd (yaozhi.com), the free sponsor of this conference, media supports yaozhi.com to meet with us in Shanghai in April, with richer content and better harvest We are looking forward to meeting you! The basic information of the meeting is introduced here If you want to learn more, please pay attention to our website.